Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
IPO Year: 2020
Exchange: NASDAQ
Website: opthea.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/8/2022 | $14.00 | Buy | H.C. Wainwright |
4/26/2022 | $25.00 | Outperform | SVB Leerink |
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an "Ask the Expert" conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea'
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows successful Institutional Entitlement Offer and institutional Placement raising approximately A$171.5m (US$113.2m1) Completion of Retail Entitlement Offer represents final stage of Opthea's approximately A$227.3m (US$150.0m1) capital raising
Gainers Ainos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 34.15% to $3.61. The company's market cap stands at $22.9 million. Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 20.99% to $2.42. The market value of their outstanding shares is at $4.4 million. Moleculin Biotech (NASDAQ:MBRX) stock moved upwards by 17.24% to $5.1. The market value of their outstanding shares is at $11.7 million. Tonix Pharmaceuticals (NASDAQ:TNXP) shares moved upwards by 12.84% to $1.23. The company's market cap stands at $3.6 million. Molecular Partners (NASDAQ:MO
Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expected in mid-CY2025
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-surge-over-400-says-oppenheimer/
Shares of Netflix, Inc. (NASDAQ:NFLX) shares rose sharply in today’s pre-market trading as the company reported better-than-expected sales for its fourth quarter. Netflix reported fourth-quarter revenue of $8.83 billion, which was up 12.5% year-over-year. The total came in ahead of a Street consensus estimate of $8.72 billion. The company reported fourth-quarter earnings per share of $2.11, which missed a Street consensus estimate of $2.21. The company, meanwhile, added 13.12 million net paid subscribers in the fourth quarter. Netflix shares jumped 10.2% to $542.48 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Getaround, Inc. (NYSE:GETR) gain
H.C. Wainwright initiated coverage of Opthea Ltd. with a rating of Buy and set a new price target of $14.00
SVB Leerink initiated coverage of Opthea Ltd. with a rating of Outperform and set a new price target of $25.00
Virtual Bell Potter Healthcare Conference, November 18, 2024 Jefferies London Healthcare Conference, November 19, 2024 MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024. Conference details are as follows: Bell Potter Healthcare ConferencePresentation:Monday, November 18, 2024, 3:00 PM AEDT (Virtual)Presenter:Frederic Guerard, Phar
Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea's innovation agenda MELBOURNE, Australia and PRINCETON, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the filing of the Notice of the Annual General Meeting and Explanatory Notes distributed to shareholders for the Company's annual general meeting to
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois. David Boyer, MD, will present an update on Opthea's wet AMD program, including highlights of the unmet medical need in wet AMD, the sozinibercept Phase 2b trial results, and the Phase 3 program designed to assess superiority in visual acuity
Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on October 2, 2024. UBS Virtual Ophthalmology Day 2024 Fireside chat: Wednesday, October 2, 2024, 4:00 PM ETPresenter:Frederic Guerard, PharmD, CEOWebcast link:https://kvgo.com/ubs/opthea-ltd-oct-2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the Company joins the S&P/ASX 300 Index, effective Monday, September 23, 2024, prior to market open in Australia. "Opthea's addition to the S&P/ASX 300 Index reflects the Company's strengthened balance sheet with proceeds from the recent financing completed in July 2024. We also reached a significant milestone by completing enrollment of close to 2,00
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 2025 MELBOURNE, Australia and PRINCETON, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the completion of its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept. The PPQ campaign consisted of the production
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced scientific presentations and a non-CME educational lunch symposium highlighting sozinibercept's potential to become the first therapy in 20 years to improve visual outcomes in wet AMD patients at the European Society of Retina Specialists Annual Conference -- EURETINA Innovation Spotlight (EIS), September 18, 2024, and the 24th EURETINA Congress, September 19
Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOURNE, Australia and PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical Company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced executive leadership changes in Commercial and Finance as well as senior hires for Biometrics, Clinical Operations and Market Access. The following
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present and participate in one-on-one investor meetings at the following two investor conferences in September 2024: H.C. Wainwright 26th Annual Global Investment ConferencePresentation:Monday, September 9, 2024, 7:00 AM ETPresenter:Frederic Guerard, PharmD, CEOThe webcast will be accessible via the link: https://journey.ct.events/view/19
6-K - Opthea Ltd (0001815620) (Filer)
6-K - Opthea Ltd (0001815620) (Filer)
6-K - Opthea Ltd (0001815620) (Filer)
6-K - Opthea Ltd (0001815620) (Filer)
6-K - Opthea Ltd (0001815620) (Filer)
6-K - Opthea Ltd (0001815620) (Filer)
6-K - Opthea Ltd (0001815620) (Filer)
6-K - Opthea Ltd (0001815620) (Filer)
6-K - Opthea Ltd (0001815620) (Filer)
6-K - Opthea Ltd (0001815620) (Filer)
Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024. Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team. Dr. Han brings over 20 years of experience building medical affairs programs and partnering across organizations to lead pre- an
MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Sujal Shah to the Company's Board of Directors (the "Board"), effective April 4, 2024. Concurrent with his appointment as non-Executive Director, Mr. Shah will also become Chairman of the Audit and Risk Committee. In conjunction with Mr. Shah's appointment, the Company also announced that Daniel Spiegelman has resigned from the Board in his role as N
MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani is a Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, and Clinical Associate Professor at the University of Nevada, Reno School of Medicine. "We are delighted to have Dr. Khanani join Opthea as Chief Medical Advisor," said Fred
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology diseases MELBOURNE, Australia, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer,
Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr. Frederic Guerard appointed as CEO and Peter Lang appointed as CFO, bringing complementary expertise to lead Opthea's next phase of growth MELBOURNE, Australia, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT))), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the company's Chief Executive Officer, Dr. Megan Baldwin, will transition to Founder and Chief Innovation Officer, effective today, reflective of the co
MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT))), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today the resignation of Dr. Joel Naor, Chief Medical Officer (CMO), effective July 15th, 2023. Dr. Naor is stepping down to pursue new opportunities and will be replaced by Dr. Kenneth Sall, MD who has been appointed as Opthea's Senior Medical Advisor. Dr. Sall will assume responsibility for safety oversight of the Opthea's Phase 3 clinical trials investigating OPT-302, a novel VEGF-C/D ‘trap' inhibitor, for the treatment of wet age-related macular dege
MELBOURNE, Australia, June 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT))), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral as a Non-Executive Director of the Company's Board of Directors. Concurrently with this appointment, Mr. Michael Sistenich has resigned as a Non-Executive Director, having served for over 7 years on the Board. Opthea's Chairman, Dr. Jeremy Levin, commented "We are immensely grateful to Michael for his contribution to Opthea. Having joined the Board in 2015, Michael has been a valued contributor to Opthea's
Key appointment as Opthea progresses Phase 3 registrational trials of OPT-302 for wet AMD MELBOURNE, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT))), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Timothy E. Morris as Chief Financial Officer (CFO), effective 24 October 2022. Mr. Morris is a veteran pharmaceutical executive based in the U.S. with extensive industry experience leading financial teams of public and private biotechnology companies. Mr. Morris' accomplishments include raising over $2.5 billion in equity and convertible
SC 13G/A - Opthea Ltd (0001815620) (Subject)
SC 13G/A - Opthea Ltd (0001815620) (Subject)
SC 13G/A - Opthea Ltd (0001815620) (Subject)
SC 13G/A - Opthea Ltd (0001815620) (Subject)
SC 13G/A - Opthea Ltd (0001815620) (Subject)
SC 13G/A - Opthea Ltd (0001815620) (Subject)
SC 13G - Opthea Ltd (0001815620) (Subject)